Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
We may have one thing in common with jellyfish, new research finds - 2Vote In favor of Your Favored Pet Consideration Administration
- 3Former 'Bachelorette' welcomes 1st baby via emergency c-section
- 4Cyclone Narelle turns Australian skies blood red in ‘apocalyptic’ scenes
- 5Blue Origin’s New Glenn rocket landed its booster on a barge at sea – an achievement that will broaden the commercial spaceflight market
- FDA official discusses potential link between COVID-19 vaccines and pediatric deaths
- Hyundai Is Keeping the i30 Alive While America Keeps Losing Cars Like It
- Airport wait times won't return to normal until Congress reaches a deal to pay TSA. Here's why they still can't come to an agreement.
- Flat Earth, spirits and conspiracy theories – experience can shape even extraordinary beliefs
- Style Narratives: A Survey of \Patterns and Styles Assessed\ Design
- Vacuum Cleaners That Are Not difficult To Use For Home
- Taylor Swift just released the 'Elizabeth Taylor' music video — but she's not the star of it
- Which salad do you believe is a definitive group pleaser? Vote!
- Charity 'feels the pinch' of higher energy prices
